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Abstract
Purpose Dihydropyrimidine dehydrogenase (DPD) defi-
ciency can lead to severe toxicity in patients treated with
standard doses of 5-fluorouracil (5-FU). Oral uracil
administration and subsequent measurement of uracil and
dihydrouracil (DHU) plasma concentrations might detect
patients with DPD deficiency. This study compares the
pharmacokinetics of uracil and DHU after oral uracil
administration in subjects with normal and deficient DPD
status.
Methods Five hundred milligrams of uracil per metre
square was administered orally to 11 subjects with normal
DPD status and to 10 subjects with reduced DPD activity.
Repeated administration (n = 3) of this dose was per-
formed in 4 subjects, and 1,000 mg uracil/m2 was admin-
istered to 4 subjects to assess intra-individual variation and
linearity of pharmacokinetics.
Results In subjects with normal DPD status, 500 mg/m2
uracil resulted in uracil Cmax levels of 14.4 ± 4.7 mg/L at
Tmax = 30.0 ± 11.6 min, and in DPD-deficient subjects,
20.0 ± 4.5 mg/L at 31.5 ± 1.1 min. The uracil AUC0[180
was 31.2 ± 5.1 mg L/h in DPD-deficient subjects, which
was significantly higher (P \ 0.05) than in the subjects
with normal DPD status (13.8 ± 3.9 mg L/h). Repeated
uracil dosing showed reproducible uracil PK in subjects
with normal DPD status, and dose elevation of uracil
suggested linear pharmacokinetics.
Conclusion The pharmacokinetics of uracil differs sig-
nificantly between subjects with a normal DPD activity and
those with a deficient DPD status. The AUC and Cmax of
uracil can be useful as a diagnostic tool to differentiate
patients with regard to DPD status.
Keywords Dihydropyrimide dehydrogenase  Uracil 
Cancer  5-fluorouracil  Pharmacokinetics
Introduction
5-Fluorouracil and its prodrug capecitabine are commonly
used chemotherapeutic drugs in the treatment of colorectal,
breast, and head and neck cancer. The intracellular
metabolism of 5-FU is complex, requiring conversion into
cytotoxic nucleotides. The main cytotoxic metabolite is
5-fluoro-20-deoxyuridine 50-monophosphate that inhibits
thymidylate synthase [1]. However, only a small proportion
of the administrated 5-FU dose is converted to cytotoxic
metabolites. Within a few hours after parenteral adminis-
tration, 70–90% of the 5-FU dose is metabolized into
inactive metabolites. DPD is the initial and rate-determin-
ing enzyme in the catabolism of 5-FU [2–5]. Patients with
a partial or complete DPD deficiency have a strongly
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reduced capacity to degrade 5FU [6, 7] or its oral prodrug
capecitabine [8, 9]. As a consequence, treatment with 5-FU
and/or capecitabine in patients with reduced DPD activity
can cause severe or life-threatening toxicity such as neu-
tropenia, diarrhea, and mucositis [10]. It was initially
estimated that in 3–5% of Caucasians, the activity of DPD
is strongly reduced due to (epi)genetic variations in the
gene encoding DPD. However, this percentage can be
disputed because the incidence of DPD deficiency depends
on the method that is used to detect it [11] and the cutoff
level chosen or determined to define DPD deficiency [12].
A recent study found DPD deficiency in 40% of the
patients included using the uracil/dihydrouracil ratio in
plasma, an observation higher than the outcome expected
with DPYD genetic polymorphism [13].
Several methods have been developed to detect patients
with reduced DPD activity, such as genotyping [14],
determination of DPD activity in peripheral blood mono-
nuclear cells (PBMCs) [4, 10], phenotyping with a breath
test using [2-13C] uracil [15–17], the administration of a
5-FU test dose [7, 18], and assessment of the endogenous
uracil/DHU plasma ratio [19–27]. A major drawback of
many of these methods is that they are costly and/or
laborious or in the case of a 5-FU test dose, potentially
toxic, thus precluding the routine implementation in clini-
cal practice for prospective screening of DPD deficiency.
To achieve the most accurate and simple method to predict
DPD deficiency prior to 5-FU- or capecitabine-based
treatment, a combined testing strategy has been proposed
[12, 21]. However, oral administration of an uracil test dose
and subsequent measurement of uracil and its metabolite
DHU in plasma might be a cheap, fast, and simple method
for screening of DPD deficiency prior to 5-FU or capecit-
abine containing therapy, which can be used clinically.
So far, only the pharmacokinetics of orally administered
13C-uracil has been reported using low doses of 50, 100,
and 200 mg uracil. The major drawback of using low doses
of uracil concerns the lower chance of reaching adequate
plasma concentrations. The use of higher uracil doses is
expected to result in a more adequate discrimination
between normal and deficient individuals due to a pro-
longed DPD enzyme saturation in DPD-deficient subjects
compared with lower doses of uracil. Moreover, this situ-
ation may better reflect the DPD enzyme dynamics in the
clinical situation when 5-FU doses of 1,000–2,000 mg are
being used. From previous work with 5-FU, we estimated
that a uracil plasma level of at least 10 mg/L would be
needed for proper discrimination between DPD-deficient
and normal DPD subjects with high sensitivity and speci-
ficity [6].
The main objective of this study was to compare the
pharmacokinetics of orally administered uracil between
healthy volunteers with normal DPD activity and patients
with DPD deficiency due to heterozygosity for a DPYD
gene mutation. Secondary objectives involved the investi-
gation of linearity of uracil pharmacokinetics at increased




Eleven subjects with a normal DPD status and ten DPD-
deficient subjects, aged 18 years and older, participated in
this study. The eleven subjects were all healthy volunteers,
and the ten DPD-deficient subjects were colorectal and
breast cancer patients who suffered CTC grade III or IV
side effects following a 5-FU or capecitabine containing
drug schedules and had DPD activity \ 5 nmol/mg pro-
tein/h. DPD activity was measured in PBMCs, and the
DPD status was considered normal or deficient when the
DPD activity in PBMCs was [ 5 nmol/mg protein/h
or \ 5 nmol/mg protein/h, respectively [11]. In all
patients, DPD deficiency was confirmed by sequence
analysis of DPYD showing heterozygosity for a patholog-
ical mutation. Heterozygosity for the c.1905 ? 1G[A
(IVS14 ? 1G[A), c.2846A[T, c.1129 - 5923C[G, and
the novel c.2579delA mutation was detected in 5, 2, 2, and
2 patients, respectively. One of the patients was heterozy-
gous for both the c.1905 ? 1G[A mutation and the
c.1129 - 5923C[G mutation.
Prior to uracil administration, blood samples were taken
to measure creatinine, alanine transaminase (ALAT), and
gamma-glutamyl transpeptidase (gamma-GT) as markers
for renal and liver function.
The study was approved by the local Medical Ethics
Committee of Diaconessen Hospital Meppel, the Nether-
lands. Informed consent was obtained from each subject.
Uracil administration
Uracil (Pharmorgana GmbH, Raubling/Rosenheim,
Germany) was administered orally at a test dose of
500 mg/m2 body surface area, calculated by the DuBois
and DuBois formula, after an overnight fast (last food
intake [ 8 h earlier). All subjects had to abstain food
during 2 h after ingesting the uracil. All the test doses were
administered between 08:00 a.m. and 09:00 a.m. to avoid
circadian effects. The uracil powder was mixed with
100–200 mL tap water, and immediately after preparation,
the suspension was ingested within a few minutes. In
addition, repeated administration on subsequent days
(n = 2 in 3 subjects and n = 1 in one subject) with
500 mg/m2 was performed in 4 volunteers to assess
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intra-individual variation, and 1,000 mg uracil/m2 was
administered to 4 volunteers to assess linearity of phar-
macokinetics, respectively.
Collection of blood samples
A cannula was placed intravenously in one arm of each
subject. Blood samples of 5 ml were collected in heparin-
containing tubes. In an intensive sampling schedule, blood
samples were collected just before and at t = 15, 30, 45,
60, 80, 100, 120, 150, 180, and 220 min (500 mg/m2) or
240 min (1,000 mg/m2) after uracil intake. Samples were
immediately placed on ice and subsequently centrifuged at
2,5009g for 10 min at 4C and stored at -20C until
analysis.
For the repeated uracil administration in the 4 subjects,
blood samples were collected according to a limited sam-
pling schedule. This schedule is based on results from an
interim analysis on intensive schedule results from both
volunteers and patients, in which T = 60 min and
T = 120 min were selected as optimal sampling points for
the limited sampling strategy.
DPD activity
The activity of DPD was determined in PBMCs using
radiolabeled thymine followed by the separation of radio-
labeled thymine from radiolabeled dihydrothymine using
reversed-phase HPLC, as described before [28].
Analytical method for uracil and dihydrouracil
Uracil and DHU plasma concentrations were measured by
a validated HPLC method described by Maring et al. [29].
Calibration samples were prepared by spiking human
heparinized plasma (Red Cross Blood Bank, Groningen,
the Netherlands) with appropriate amounts of uracil and
5,6-DHU (Sigma Chemical Co, Zwijndrecht, the Nether-
lands). Uracil was quantified at 266 nm and DHU at
205 nm. The internal standard chlorouracil was quantified
at both wavelengths. The limit of quantification in plasma
was 0,004 mg/L for both uracil and DHU.
Pharmacokinetic and statistical analysis
The pharmacokinetic parameters Tmax, Cmax, and
AUC0–180 min were calculated with Phoenix
TM Winnonlin
Version 6 (Pharsight Products, CA) using noncompart-
mental analysis. Mean plasma clearance was calculated
with the formula Dose/AUC. Statistical analysis was per-
formed by using SPSS version 16.0 (SPSS inc, Chicago,
IL). Normality of data was tested by performing a Kol-
mogorov–Smirnov test.
To examine whether the uracil and DHU plasma con-
centrations and derived pharmacokinetic parameters dif-
fered between subjects with a normal DPD status and those
with DPD deficiency, an unpaired Student’s t test was
performed on data obtained from the 500 mg/m2 dose. To
investigate whether the distribution of gender in both
groups differs between the DPD-deficient and normal
individuals, chi-square statistic was used. One-way
ANOVA analysis was performed on the uracil and DHU
values measured in plasma at t = 60 and 120 min in the
four volunteers after repeated 500 mg/m2 doses to study
the inter- and intrasubject variability.
Results
The characteristics of the subjects included in this study are
displayed in Table 1. No differences between the two
groups were observed (P [ 0.05) except for age, DPD
activity, and disease status. The HPLC method that was
used in this study revealed fully separated peaks for uracil
and DHU in the chromatogram as is depicted in Fig. 1. The
mean uracil and DHU plasma concentrations in the 11
subjects with normal DPD and in the 10 DPD-deficient
subjects following an uracil dose of 500 mg/m2 are
depicted in Fig. 2, and the estimated pharmacokinetic
parameters Tmax, Cmax, AUC0–180 min, and the mean Cl are
displayed in Table 2. Tmax of uracil, AUC0–180 min, and Cl
of DHU did not differ between the two groups (P [ 0.05).
All the other displayed parameters differed significantly
(P \ 0.05). After reaching Tmax, the decline of uracil
concentration in both groups followed zero-order kinetics,
which suggests that the DPD enzyme is fully saturated at
the administered dose in both groups. In the subjects with
normal DPD, after t = 100 min, the elimination changed
gradually from zero order to first order, which resulted in
an exponential decline. The same phenomenon occurred in
DPD-deficient subjects, although at a later stage (after
t = 150 min).
In subjects with normal DPD activity, uracil was com-
pletely eliminated within approximately 180 min, whereas
in DPD-deficient subjects, the uracil plasma concentration
was still 2.5 ± 2.1 mg/L indicating that in DPD-deficient
individuals, the clearance of uracil was decreased. In
addition, due to the reduced DPD activity, the reaction rate
of the formation and the absolute amount of DHU were
reduced in the group of DPD-deficient subjects. The uracil
and DHU plasma concentrations measured in DPD-defi-
cient subjects differed significantly (P \ 0.05) as com-
pared to the individuals with normal DPD except for uracil
at t = 15 min (P = 0.071) and for DHU levels at t = 15,
120, 150, and 180 min (P = 0.149, P = 0.111, P = 0.087,
and P = 0.363, respectively).
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Comparable uracil concentrations at t = 60 and 120 min
were observed in subjects with normal DPD status who were
tested multiple times. However, significant differences were
observed for DHU levels at t = 60 and 120 min (P = 0.012
resp. P = 0.001).
Figure 3 shows the plasma concentrations of uracil and
DHU after administration of 1,000 mg uracil/m2 compared
with 500 mg uracil/m2 in subjects with normal DPD status.
The Cmax of both curves is reached after approximately
30 min (Tmax). Only after 45 min, the uracil levels differed
significantly between both dosages. For DHU, the con-
centrations after ingestion of both doses differed not
significantly the first 100 min, but after this point, the DHU
concentrations measured in the group of 1,000 mg/m2
were significantly higher. The Cmax values of uracil and
DHU (Table 2) at 1,000 mg/m2 are, respectively, 1.7 ± 0.3
and 1.5 ± 0.4 times higher compared with those after
500 mg/m2.
Discussion
In this study, it is shown that the pharmacokinetics of uracil
after an oral uracil dose of 500 mg/m2 was significantly
different in subjects with DPD deficiency as compared to
those with a normal DPD status suggesting that oral uracil
administration may be useful as a test to determine patients
with DPD deficiency.
The patient characteristics of the two groups in which
we studied uracil and DHU pharmacokinetics were com-
parable except for DPD status, age, and disease state. The
subjects with normal DPD consisted of young healthy
individuals, in contrast to the subjects with DPD defi-
ciency, who were all colorectal and breast cancer patients.
Aging involves progressive impairments in the functional
reserve of multiple organs, which might also affect drug
metabolism and pharmacokinetics [30]. With age, the liver
mass and its perfusion decreases causing a diminished first
pass effect of highly cleared drugs, and renal clearance of
Table 1 Patient and volunteer
characteristics
Values are displayed as
mean ± SD
Normal DPD




Age (years) 38 ± 9 62 ± 12 \0.001
Sex (male/female) 5/6 4/6 Chi square = 0.002
Weight (kg) 74 ± 10 76 ± 15 0.636
Height (cm) 177 ± 9 173 ± 5 0.154
PBMC DPD (nmol/mg/L) 7.2 ± 1.3 3.6 ± 0.8 \0.001
Serum creatinine (lmol/L) 80 ± 10 78 ± 18 0.707
Serum ALT (U/L) 20 ± 8 25 ± 5 0.104
Serum gamma GT (U/L) 16 ± 6 39 ± 40 0.160
Fig. 1 Representative chromatogram obtained from a blood sample
of a DPD-deficient patient at t = 101 min after oral intake of 500 mg/
m2 uracil. The chromatogram was recorded at 205 nm. The uracil and
dihydrouracil concentrations were estimated as 7.60 and 2.03 mg/L,
respectively
Fig. 2 Concentration–time profile of uracil and DHU in subjects with
normal DPD (n = 11) and DPD-deficient subjects (n = 10) after oral
intake of 500 mg/m2 uracil suspension. The results shown are the
mean ± SD
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drugs is reduced by the loss of kidney function [31]. The
liver contains a high amount of DPD, so increasing age
might lead to reduced first pass effect and metabolism of
uracil in the liver causing higher plasma concentrations in
elderly compared with younger individuals. In addition, in
cancer patients, metastases of the liver and steatosis caused
by systemic chemotherapy [32] can reduce liver drug
metabolism, which may also lead to changes in uracil
metabolism. However, Maring et al. [33] described that
extensive hepatic replacement due to liver metastases had
no effect on 5-fluorouracil pharmacokinetics, indicating
that the amount of DPD is probably not influenced by
reduction in liver function. In addition, in our study pop-
ulation of DPD-deficient patients receiving systemic che-
motherapy, no significant differences were observed in
liver function or serum creatine compared with the group
of healthy individuals. As a result of these findings, we
consider it unlikely that the 2.6-fold decrease in clearance
of uracil can be ascribed to differences in age or disease
state between the two groups. The differences between the
2 uracil curves representing both the groups with and
without DPD deficiency at 500 mg/m2 are caused by the
amount of DPD available in deficient subjects, which is
lower than in subjects with normal DPD activity causing
reduced clearance of uracil. Mattison et al. [15] evaluated
fixed doses of 2-13C-uracil of 100, 200, and 300 mg as well
as doses adjusted to body weight (1,3,6, and 12 mg/kg).
They demonstrated with their uracil breath test that an
administered dose of 6 mg/kg 2-13C-uracil generated less
variable Cmax and Tmax than single fixed doses of 100, 200,
or 300 mg. The dose of 500 mg uracil/m2 used in our study
is in range with the 2-13C-uracil dose of 12 mg/kg that was
also used by Mattison et al. and with the commonly applied
5-FU bolus doses of 400–600 mg/m2 in the treatment of
colorectal and breast cancer [34–37]. The gastrointestinal
absorption of uracil is a pharmacokinetic first-order pro-
cess, and the elimination follows a reversible and saturable
Michaelis–Menten kinetics [17]. When DPD is saturated,
the elimination of uracil follows zero-order kinetics. The
formation of DHU depends on the Km of DPD and the
amount of uracil and enzyme present. When all the present
DPD enzyme is saturated, the metabolism of uracil will
depend on the absolute amount of DPD present and not on
the amount of uracil, i.e., if the same dose of uracil is
administered to two individuals with different enzyme
levels, the individual with the highest amount of enzyme
will have the highest ‘‘zero-order’’ reaction rate and the
lowest Cmax of both individuals. So, in order to discrimi-
nate between individuals with a normal DPD activity and
those with a DPD deficiency, the uracil dose used needs to
be high enough to saturate the DPD enzyme both in indi-
viduals with and without DPD deficiency in order to
achieve significant different plasma levels.
For oral uracil to be used as a diagnostic test, the
pharmacokinetics of uracil between patients with and
without DPD deficiency has to be clearly discriminating.
Mattison et al. [38] describe that the AUC following a dose
of 6 mg/kg 2-13C uracil is significantly different in subjects
with normal DPD activity versus partial DPD deficiency.
Table 2 Pharmacokinetic parameters of 500 mg/m2 and 1,000 mg/m2 in volunteers and 500 mg/m2 in patients




mg/m2 (n = 11)
DHU 500
mg/m2 (n = 11)
Uracil 500
mg/m2 (n = 10)
DHU 500
mg/m2 (n = 10)
Uracil DHU Uracil 1,000
mg/m2 (n = 4)
DHU 1,000
mg/m2 (n = 4)
Tmax (min) 30.0 ± 11.6 104.5 ± 23.4 31.5 ± 11.1 166.0 ± 55.6 0.765 0.007 33.8 ± 18.9 195.0 ± 57.4
Cmax (mg/L) 14.4 ± 4.7 3.0 ± 0.9 20.0 ± 4.5 2.2 ± 0.9 0.011 0.046 24.1 ± 11.9 5.2 ± 1.1
AUC0–180 min
(mg h/L)
13.8 ± 3.9 5.9 ± 1.9 31.2 ± 5.1 4.4 ± 1.7 \0.001 0.074 36.0 ± 14.4 8.0 ± 2.3
Clmean (L/min) 1.3 ± 0.5 3.1 ± 1.8 0.5 ± 0.1 4.0 ± 1.6 \0.001 0.230 1.1 ± 0.6 4.5 ± 1.7
Values are displayed as mean ± SD
Fig. 3 Concentration–time profile of uracil and DHU in subjects with
normal DPD activity after oral administration of a dose of 500 mg/m2
(n = 11) and 1,000 mg/m2 (n = 4) uracil suspension. The results
shown are the mean ± SD
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This is in line with the results we found using a dose
500 mg/m2 uracil. For a broad clinical use, a diagnostic test
has to be simple, cheap, sensitive, and specific. The uracil
breath test is expensive because of the use of 2-13C uracil
and breath bags, and the technique of IR spectrophotometry
for analysis of exhaled samples is not available in every
hospital. Our test might be more cost effective and might
lead to quick test results since the price of 1 gram uracil is
about 1 US$ and the HPLC equipment that is used for
analysis is common in most hospitals for therapeutic drug
monitoring purposes. If the HPLC equipment is not avail-
able at the testing site, the plasma samples have to be stable
enough to be transported. Prior to this study, the stability of
U and DHU in whole blood and plasma was determined.
The results show that uracil in whole blood can be stored
at 4C for up to 4 h. The degradation of U and DHU in
plasma was less than 2% during 24 h at room temperature.
We therefore concluded that the stability in plasma is
sufficient enough to perform the analytical extraction pro-
cedure without further precautions and that the plasma
samples are suitable for transportation within 24 h. As a
result, our test can be incorporated broadly into common
clinical practice. However, a disadvantage of the current
setup of the test is the intensive blood sampling scheme
that takes 4 h to perform and makes the patient intense.
The test has to be further optimized into a limited sampling
strategy to be more patient friendly. Based on a limited
sampling strategy, the parameters AUC, clearance, and
Cmax are less suitable for discriminating, but the uracil and/
or DHU concentrations or U/DHU ratio at selected time
points (e.g. 120 min after administration) might be. At this
stage, it is unclear if monitoring DHU concentrations can
be useful in a limited sampling strategy setting since we
found only slightly different values in DHU pharmacoki-
netic parameters in both groups. This might be explained
by the fact that the DHU levels are not only determined by
the degradation of uracil by DPD but also by its volume
of distribution and the subsequent hydrolysis of DHU
into N-carbamyl-b-alanine by dihydropyrimidinase. We
conclude that uracil administration at a single dose of
500 mg/m2 leads to significant and reproducible differ-
ences in pharmacokinetics of uracil and DHU between
volunteers with a normal DPD activity and DPD-deficient
patients. AUC0–180 min and Cmax might be useful to detect
partial DPD deficiency. In addition, uracil doses above
500 mg/m2 have no discriminating benefits but will only
result in a right shift of the uracil and DHU concentration
curve and unnecessary longer exposition to high uracil
levels. The results presented here points toward a promis-
ing development of an oral uracil challenge as a diagnostic
test for DPD deficiency. The sensitivity and specificity of
this test are currently investigated in a larger population of
cancer patients with and without DPD deficiency.
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